Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HUPSN
ADC Name
cot-APTEDB-SN38
Synonyms
cot APTEDB SN38
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Glioblastoma [ICD11:2A00]
Investigative
Antibody Name
Anti-EDB Ab cot
  Antibody Info 
Antigen Name
Vesicle-associated membrane protein 8 (VAMP8)
  Antigen Info 
Payload Name
Active metabolite of irinotecan SN38
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mal-PEG4-Ala
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 22.2
%
U-87MG cells
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 22.20% (Day 8) Positive EDB expression (EDB +++/++)
Method Description
BALB/c nude mice bearing U87MG tumors (450 mm3) were injected intravenously via the tail vein with Abcot (10 mg/kg) or cot-APTEDB-SN38 (equivalent to 2 mg SN38/kg).
In Vivo Model U87MG CDX model
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy. Mol Pharm. 2019 Jan 7;16(1):165-172. doi: 10.1021/acs.molpharmaceut.8b00924. Epub 2018 Dec 17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.